"Giving voice to the needs of the German Medical Marijuana/Cannabis Patient Community" / Cenedella, Patient Advocate since 1977.

The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM

Leave a comment

The Act on the Amendment of Drugs and Other Provisions, which entered into force on 10 March 2017, has expanded the scope for the prescription of cannabis medicines. The Act provides for the establishment of a government agency, the so-called cannabis agency, in accordance with the provisions of the United Nations Unity Treaty of 1961 on United Nations drugs. This will control and control the cultivation of cannabis for medical purposes in Germany.

Until cannabis is available for medical purposes from German cultivation, the demand is still covered by imports, for which the cannabis agency is not responsible (further information – see Bundesopiumstelle ).

The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM . It controls cultivation, harvesting, processing, quality testing, storage, packaging as well as delivery to wholesalers and pharmacists or manufacturers. The cannabis agency will take possession of the cannabis for medical purposes after the harvest.

The harvest is not transported to the BfArM , it is not stored there, nor is it redistributed from there. These steps will be located spatially at the respective construction companies or other commissioned companies.

The cultivation is therefore not carried out in the BfArM or by the BfArM itself, but by companies selected in a Europe-wide tender procedure and commissioned by the cannabis agency. The procedure takes into account all drug and narcotic drug requirements.

The tender procedure has now been published in the Official Journal of the European Union.
The following link leads to the tender documents: Supplement to the Official Journal of the European Union

Communication in connection with the tendering procedure takes place exclusively through the electronic award platform.

Cannabis will be grown exclusively for medical purposes. It is therefore a medicine. Only cannabis grown according to the guidelines of the Good Agricultural and Collection Practice (GACP ) will be used, which corresponds to the specifications of the Monograph “Cannabis Blossoms” ( DAB ) and the Requirements of the other relevant monographs and guidelines. This ensures the availability of cannabis for medical purposes in reproducible quality in accordance with drug laws. The cannabis for medical purposes is also subject to the provisions of the law on narcotic drugs.

The cannabis agency will set a manufacturer’s fee and sell the cannabis to cannabis drug manufacturers, wholesalers or pharmacies. The cannabis agency is not allowed to make any profits or surpluses. In the case of pricing, however, the personnel and material costs incurred by the BfArM are taken into account. However, the cannabis agency has no influence on the actual sales price in the pharmacy. The distribution channels of manufacturers and dealers will comply with the legal regulations and are thus identical with the regulations for the distribution of other drugs containing narcotic drugs.

Here you can find information about the cannabis agency and the cannabis cultivation of cannabis controlled by the cannabis agency for medical purposes:

Why must a so-called cannabis agency be established?
Where is the cannabis agency located?
What are the tasks of the cannabis agency?
What are the foundations of the tendering procedure?
How do I participate in the tender procedure?
Can you ask questions about the tender procedure?
How is the quality of the cannabis cultured in Germany to be used in the future?


Philip J. Cenedella IV Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. I have served as a Board of Director for the World Trade Center San Diego, as a Lead Consultant for Deutsche Telekom's Executive Board, Founded the Dayton Human Trafficking Accords and have been a C-Level Business Development Executive in the technology sector. Since 2016 I have been fulltime in the legal medical marijuana industry, helping companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues, but be rest assured I am knowledgeable and can assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource, on the ground in Europe! Philip J. Cenedella IV Call +1.888.206.3264 USA + GERMANY Skype: philip.j.cenedella eMail: LinkedIN:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.